Courtney Flaherty

Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis

January 17th 2025

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

January 17th 2025

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

January 17th 2025

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

January 17th 2025

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

LOAd703 Oncolytic Adenovirus Receives FDA Fast Track Designation for Pancreatic Cancer

January 17th 2025

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Zanidatamab Plus Evorpacept Shows Early Activity, Tolerability in Pretreated HER2+ Breast Cancer

January 17th 2025

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL

January 16th 2025

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

January 16th 2025

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Dr Westbrook on Clinical Trials That Have Shaped the Non-ccRCC Treatment Paradigm

January 16th 2025

Thomas Westbrook, MD, discusses the non–clear cell renal cell carcinoma research that informs his clinical practice.

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups

January 15th 2025

Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

January 14th 2025

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

January 14th 2025

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

January 14th 2025

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

January 14th 2025

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Dr Park on Patient and Disease Factors that Affect Treatment Decisions for mHSPC

January 13th 2025

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Dr Ghia on a Pooled Analysis of OS Outcomes With Ibrutinib Plus Venetoclax in CLL

January 13th 2025

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD

January 13th 2025

Dr Piotrowska on the Importance of Genomic Profiling to Identify HER2 Mutations in NSCLC

January 13th 2025

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

Zanubrutinib Plus Obinutuzumab/Venetoclax Associated With Durable uMRD4 Outcomes in Treatment-Naive CLL

January 13th 2025

Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.